Indogulf Cropsciences Limited has informed the Exchange about Transcript

Management guided margin improvementMulti-year targets disclosedInvestor Communications View source PDF Explain this filing

IGCL · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+1.2%Reaction day

₹109.77

prior close

₹108.55

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used-0.1%+1.3% vs market

Pesticides & Agrochemicals peers, median of 25sector+0.5%+0.7% vs sector

On the reaction day the stock moved 1.3 pts more than Nifty Microcap 250 and 0.7 pts more than its Pesticides & Agrochemicals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+2.4

10m

+1.2

15m

+1.1

30m

+1.1

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+1.2-0.1+1.3+0.5+0.7

Next day

-0.7+0.2-0.9+1.1-1.8

+5.2-0.4+5.6+0.4+4.8

+3.2-0.5+3.8-0.8+4.0

-1.1-2.2+1.2-2.1+1.1

-3.0-2.9-0.1-2.6-0.3

-4.6-1.8-2.8-3.3-1.3

15d

+1.4+0.3+1.1-4.3+5.7

-0.3+1.5-1.8-4.6+4.3

-1.1-0.5-0.6-10.4+9.3

-13.0-1.3-11.7-18.2+5.2

UpDownMarket · Nifty Microcap 250Sector · Pesticides & Agrochemicals peers, median of 25Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Indogulf Cropsciences reported a strong Q1 FY26 with revenue of INR 1,894 million, up 43.3% year-on-year, driven by 73.4% growth in domestic B2B and 17% growth in B2C segments. EBITDA grew 66.7% YoY to INR 99 million and profit after tax more than tripled to INR 39 million (+187.4% YoY). Crop protection contributed over 90% of revenue, while the biologicals segment grew 24.1% and the new subsidiary brand 'Giraffe' (AGPL) contributed 6% of revenue. Management guided for 30-35% revenue growth in FY26 with similar aspiration for FY27-FY28, improving EBITDA margins, and stated that a new Unit 5 (including a dry flowable plant) will be commissioned this fiscal year, expanding capacity by 50-60% with peak sales potential of INR 1,700-2,000 crores.

Likely market impact

Positive for shareholders — the company posted strong top-line and bottom-line growth, and management's guidance for 30-35% annual revenue growth with margin expansion signals confidence. However, the stock may react to the mixed signal that Q1 gross margins dipped 258 bps due to a higher B2B mix, though this is expected to reverse in Q2 when B2C and biologicals contribute more.